Debiopharm S.A.
Records under this name other than patents Debiopharm S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,188,696 | Pharmaceutical Compositions Formerly held Lapsed on the fee record Ended Jan 29, 2023 · High confidence | Lapsed on the fee record | Ended Jan 29, 2023 | High confidence |
| US 8,211,940 | Oxaliplatin active substance with a very low content of oxalic acid Term ended Term ended Jul 2, 2022 · From the USPTO record | Term ended | Term ended Jul 2, 2022 | From the USPTO record |
| US 7,012,072 | Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same Term ended Term ended Mar 7, 2022 · From the USPTO record | Term ended | Term ended Mar 7, 2022 | From the USPTO record |
| US 7,070,796 | Pharmaceutically stable oxaliplatinum preparation for parenteral administration Term ended Term ended Jan 28, 2022 · From the USPTO record | Term ended | Term ended Jan 28, 2022 | From the USPTO record |
| US 6,989,438 | Process for the purification of EPI-HNE proteins Formerly held Term ended Term ended Dec 21, 2021 · From the USPTO record | Term ended | Term ended Dec 21, 2021 | From the USPTO record |
| US 6,814,982 | Suspension of an EPI-HNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses Formerly held Term ended Term ended Oct 26, 2021 · From the USPTO record | Term ended | Term ended Oct 26, 2021 | From the USPTO record |
| US 8,450,281 | Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy Lapsed on the fee record Ended May 28, 2021 · From the USPTO record | Lapsed on the fee record | Ended May 28, 2021 | From the USPTO record |
| US 6,866,857 | Oxalipatinum preparation packaging Term ended Term ended Oct 13, 2019 · From the USPTO record | Term ended | Term ended Oct 13, 2019 | From the USPTO record |
| US RE40,987 | Cyclosporin with improved activity profile Term ended Term ended Jun 30, 2019 · From the USPTO record | Term ended | Term ended Jun 30, 2019 | From the USPTO record |
| US 8,962,637 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors Formerly held Lapsed on the fee record Ended Feb 24, 2019 · From the USPTO record | Lapsed on the fee record | Ended Feb 24, 2019 | From the USPTO record |